The European Commission (EC) has approved Celltrion ’s Omlyclo (CT-P39) - the first and only omalizumab biosimilar for ...
Shares in Merus rose by 15% in premarket trading, following the announcement of positive Phase II data to be presented at ...
MSD licenced the antibody-drug conjugate (ADC) therapy, sacituzumab tirumotecan, from China-based Sichuan Kelun-Biotech in ...
Biocon has entered an exclusive licence and supply agreement with Handok to commercialise synthetic Liraglutide in South ...
Grey Wolf Therapeutics has concluded an oversubscribed $50m in Series B financing expansion to advance its antigen modulation ...
Avutometinib won orphan drug designation from the US Food and Drug Administration (FDA) in March 2024. The agency designated ...
AstraZeneca is set to invest $1.5bn in a new manufacturing facility in Singapore dedicated to the production of antibody drug ...
AstraZeneca has entered into a worldwide licence and option agreement with Nona Biosciences for a preclinical monoclonal ...
The EC has granted marketing authorisation for Sandoz’s biosimilars, Wyost (denosumab) and Jubbonti (denosumab) for ...
The sales for Pfizer’s Covid products, Comirnaty and Paxlovid, decreased by 88% and 50% respectively in Q1 this year, ...
Genmab has concluded the previously announced acquisition of clinical-stage biotechnology company ProfoundBio in a $1.8bn ...
Otsuka Pharmaceutical has axed the development of its dementia drug, AVP-786, following a disappointing Phase III readout ...